Wall Street Analysts Predict a 45.3% Upside in Catalyst (CPRX): Here's What You Should Know

Core Viewpoint - Catalyst Pharmaceutical (CPRX) shows potential for significant upside, with a mean price target of $34 indicating a 45.3% increase from the current price of $23.4 [1] Price Targets and Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $1.63, where the lowest estimate is $32.00 (36.8% increase) and the highest is $36.00 (53.9% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts are optimistic about CPRX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, with a 15.4% increase in the Zacks Consensus Estimate for the current year [11][12] - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, and reliance solely on them may not yield favorable returns [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]